ArticleJournal of bioenergetics and biomembranes2025
Mechanism of LncRNA CBR3-AS1 in regulating pyroptosis of intestinal epithelial cells in ulcerative colitis.
Article in Journal of bioenergetics and biomembranes, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Combined Serum Expression of lncRNA CBR3-AS1 and miR-3163: Prognostic Significance and Underlying Mechanism in Severe Pneumonia.The clinical respiratory journal · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Ulcerative colitis (UC) is a common chronic relapsing inflammatory disease that threatens human life. This study aims to explore the mechanism of LncRNA CBR3-AS1 in pyroptosis of intestinal epithelial cells in UC. The levels of CBR3-AS1, KLF2, and SUGT1 in UC cells were detected. After downregulating CBR3-AS1 expression, cell viability and pyroptosis were measured, followed by the detection of SOD and MDA levels. The binding of CBR3-AS1 to EZH2, enrichment of EZH2 and H3K27me3 on the KLF2 promoter, and binding of KLF2 to the SUGT1 promoter were assayed. The role of CBR3-AS1 in pyroptosis was validated in animal models. We found that CBR3-AS1 and SUGT1 were increased in UC cells, and KLF2 was decreased. After downregulation of CBR3-AS1, cell viability was increased and pyroptosis was alleviated. CBR3-AS1 recruited EZH2 to occupy the KLF2 promoter, leading to increased H3K27me3 levels and suppressed KLF2 expression, reducing the enrichment of KLF2 on the SUGT1 promoter, finally promoting SUGT1 expression. SUGT1 overexpression or KLF2 downregulation alleviated the protective effect of silencing CBR3-AS1 on pyroptosis in UC cells. CBR3-AS1 downregulation alleviates cell pyroptosis in colonic tissues. In conclusion, CBR3-AS1 exacerbated pyroptosis of intestinal epithelial cells in UC via the KLF2/SUGT1 pathway.
Indexed as
Identifiers
40257734What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.